Jefferies Group reissued their hold rating on shares of Radius Health Inc. (NASDAQ:RDUS) in a research note released on Tuesday. Jefferies Group currently has a $46.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright started coverage on Radius Health in a report on Monday, May 23rd. They set a buy rating and a $55.00 price objective on the stock. Maxim Group downgraded Radius Health from a hold rating to a sell rating and set a $24.00 price objective on the stock. in a report on Thursday, August 4th. Canaccord Genuity set a $85.00 price objective on Radius Health and gave the company a buy rating in a report on Monday. Zacks Investment Research downgraded Radius Health from a hold rating to a sell rating in a report on Monday, August 8th. Finally, Cowen and Company reaffirmed a buy rating on shares of Radius Health in a report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $63.51.

Radius Health (NASDAQ:RDUS) opened at 57.41 on Tuesday. The stock’s 50 day moving average price is $55.07 and its 200 day moving average price is $41.19. The firm’s market capitalization is $2.47 billion. Radius Health has a 12 month low of $24.75 and a 12 month high of $77.10.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.06. During the same period last year, the business earned ($0.61) earnings per share. Equities research analysts expect that Radius Health will post ($3.97) earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Brookside Capital Management LLC boosted its stake in shares of Radius Health by 54.6% in the first quarter. Brookside Capital Management LLC now owns 3,136,374 shares of the biopharmaceutical company’s stock valued at $98,608,000 after buying an additional 1,107,057 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Radius Health by 13.5% in the second quarter. Vanguard Group Inc. now owns 2,615,168 shares of the biopharmaceutical company’s stock valued at $96,107,000 after buying an additional 311,547 shares during the last quarter. State Street Corp boosted its stake in shares of Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock valued at $49,938,000 after buying an additional 453,302 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Radius Health by 22.4% in the second quarter. Farallon Capital Management LLC now owns 1,535,000 shares of the biopharmaceutical company’s stock valued at $56,411,000 after buying an additional 281,305 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Radius Health by 2.5% in the first quarter. BlackRock Fund Advisors now owns 1,367,137 shares of the biopharmaceutical company’s stock valued at $42,983,000 after buying an additional 33,421 shares during the last quarter. Institutional investors own 99.91% of the company’s stock.

About Radius Health

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.